-
Urabrelimab (SRF231) is an anti-CD47 monoclonal antibody, blocking the CD47-SIRPα interaction. It has the potential to research anticancer. -
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells. -
MS159 is a frist-In-class nuclear receptor binding SET NSD2 PROTAC degrader for multiple myeloma research. -
Panobinostat, a potent and orally active non-selective HDAC inhibitor, exhibits antineoplastic activities. -
Oprozomib (PR-047) is an orally active peptide epoxyketone proteasome inhibitor. -
Iberdomide (CC-220) is an orally active cereblon (CRBN) E3 ligase modulator (CELMoD) with antitumor and immunostimulatory activities。 -
M3258 is an orally bioavailable, potent, reversible, and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. -
Lenalidomide, a CRBN ligand, is an orally active immunomodulator that effective treatment for myelodysplastic syndrome and multiple myeloma. -
dCBP-1 is a potent and selective degrader of p300/CBP based on PROTAC. dCBP-1 is exceptionally potent at killing multiple myeloma cells. -
BMS-P5 is an orally active PAD4 inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model
Categories
Others
Archives
- January 2023 (2)
- August 2022 (1)
- July 2022 (1)
- May 2022 (1)
- September 2021 (1)
- August 2021 (1)
- May 2021 (1)
- February 2021 (1)
- December 2020 (1)
- April 2020 (2)
- August 2019 (2)
- July 2019 (1)
- May 2019 (1)
